Best Momentum Stocks to Buy for May 6th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 6^th:

MAIA Biotechnology, Inc. MAIA: This immuno-oncology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 44.4% over the last 60 days.

MAIA Biotechnology, Inc. Price and Consensus

MAIA Biotechnology, Inc. price-consensus-chart | MAIA Biotechnology, Inc. Quote

MAIA’s shares gained 0.5% over the last three months compared with the S&P 500’s decline of 5.6%. The company possesses a Momentum Score  of A.

MAIA Biotechnology, Inc. Price

MAIA Biotechnology, Inc. price | MAIA Biotechnology, Inc. Quote

Byrna Technologies Inc. BYRN: This non-lethal defense technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 25% overthe last 60 days.

Byrna Technologies Inc. Price and Consensus

Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote

Byrna’s shares gained 33.8% over the last six months compared with the S&P 500’s decline of 4.7%. The company possesses a Momentum Score of B.

Byrna Technologies Inc. Price

Byrna Technologies Inc. price | Byrna Technologies Inc. Quote

OncoCyte Corporation OCX: This precision diagnostics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 39.3% over the last 60 days.

OncoCyte Corporation Price and Consensus

OncoCyte Corporation price-consensus-chart | OncoCyte Corporation Quote

OncoCyte’s shares gained 45.3% over the last three months compared with the S&P 500’s decline of 5.6%. The company possesses a Momentum Score of B.

OncoCyte Corporation Price

OncoCyte Corporation price | OncoCyte Corporation Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research